Plasmid Manufacturing For Gene Therapies: An Outsourcing Partnership
Source: Ajinomoto Bio-Pharma Services
With an increased demand for plasmids for targeted gene therapeutic delivery, partnering with a CDMO equipped with the capacity, expertise and equipment for plasmid DNA production is critical to ensuring a stable therapeutic supply.
Ajinomoto Bio-Pharma Services, an industry leader in microbial fermentation, discusses why optimizing, scaling-up and manufacturing plasmids are necessary for clinical to commercial program success and how their proven expertise and capabilities in cGMP production of biotherapeutics enable a strong, client-focused partnership, ensuring market success.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Ajinomoto Bio-Pharma Services
This website uses cookies to ensure you get the best experience on our website. Learn more